A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

Clinical trial NCT05548296 · RECRUITING

Trial details

NCT number: NCT05548296
Sponsor: Acrivon Therapeutics
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Endometrial Adenocarcinoma

Start date: 2022-08-29
Primary completion: 2027-05-30
Enrollment: 350

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.